Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer

Zhong Chen, Xun Lan, Dayong Wu, Benjamin Sunkel, Zhenqing Ye, Jiaoti Huang, Zhihua Liu, Steven K. Clinton, Victor X Jin, Qianben Wang

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Glucocorticoids (GCs) have been widely used as coadjuvants in the treatment of solid tumours, but GC treatment may be associated with poor pharmacotherapeutic response or prognosis. The genomic action of GC in these tumours is largely unknown. Here we find that dexamethasone (Dex, a synthetic GC)-regulated genes in triple-negative breast cancer (TNBC) cells are associated with drug resistance. Importantly, these GC-regulated genes are aberrantly expressed in TNBC patients and are associated with unfavourable clinical outcomes. Interestingly, in TNBC cells, Compound A (CpdA, a selective GR modulator) only regulates a small number of genes not involved in carcinogenesis and therapy resistance. Mechanistic studies using a ChIP-exo approach reveal that Dex- but not CpdA-liganded glucocorticoid receptor (GR) binds to a single glucocorticoid response element (GRE), which drives the expression of pro-tumorigenic genes. Our data suggest that development of safe coadjuvant therapy should consider the distinct genomic function between Dex- and CpdA-liganded GR.

Original languageEnglish (US)
Article number8323
JournalNature Communications
Volume6
DOIs
StatePublished - Sep 16 2015

Fingerprint

glucocorticoids
Triple Negative Breast Neoplasms
Glucocorticoid Receptors
breast
Glucocorticoids
cancer
Ligands
ligands
Genes
genes
Tumors
therapy
compound A
Response Elements
Therapeutics
tumors
Drug Resistance
Dexamethasone
Modulators
Neoplasms

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. / Chen, Zhong; Lan, Xun; Wu, Dayong; Sunkel, Benjamin; Ye, Zhenqing; Huang, Jiaoti; Liu, Zhihua; Clinton, Steven K.; Jin, Victor X; Wang, Qianben.

In: Nature Communications, Vol. 6, 8323, 16.09.2015.

Research output: Contribution to journalArticle

Chen, Z, Lan, X, Wu, D, Sunkel, B, Ye, Z, Huang, J, Liu, Z, Clinton, SK, Jin, VX & Wang, Q 2015, 'Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer', Nature Communications, vol. 6, 8323. https://doi.org/10.1038/ncomms9323
Chen, Zhong ; Lan, Xun ; Wu, Dayong ; Sunkel, Benjamin ; Ye, Zhenqing ; Huang, Jiaoti ; Liu, Zhihua ; Clinton, Steven K. ; Jin, Victor X ; Wang, Qianben. / Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. In: Nature Communications. 2015 ; Vol. 6.
@article{4f795ae8d46943199198e36dc3ba72fe,
title = "Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer",
abstract = "Glucocorticoids (GCs) have been widely used as coadjuvants in the treatment of solid tumours, but GC treatment may be associated with poor pharmacotherapeutic response or prognosis. The genomic action of GC in these tumours is largely unknown. Here we find that dexamethasone (Dex, a synthetic GC)-regulated genes in triple-negative breast cancer (TNBC) cells are associated with drug resistance. Importantly, these GC-regulated genes are aberrantly expressed in TNBC patients and are associated with unfavourable clinical outcomes. Interestingly, in TNBC cells, Compound A (CpdA, a selective GR modulator) only regulates a small number of genes not involved in carcinogenesis and therapy resistance. Mechanistic studies using a ChIP-exo approach reveal that Dex- but not CpdA-liganded glucocorticoid receptor (GR) binds to a single glucocorticoid response element (GRE), which drives the expression of pro-tumorigenic genes. Our data suggest that development of safe coadjuvant therapy should consider the distinct genomic function between Dex- and CpdA-liganded GR.",
author = "Zhong Chen and Xun Lan and Dayong Wu and Benjamin Sunkel and Zhenqing Ye and Jiaoti Huang and Zhihua Liu and Clinton, {Steven K.} and Jin, {Victor X} and Qianben Wang",
year = "2015",
month = "9",
day = "16",
doi = "10.1038/ncomms9323",
language = "English (US)",
volume = "6",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer

AU - Chen, Zhong

AU - Lan, Xun

AU - Wu, Dayong

AU - Sunkel, Benjamin

AU - Ye, Zhenqing

AU - Huang, Jiaoti

AU - Liu, Zhihua

AU - Clinton, Steven K.

AU - Jin, Victor X

AU - Wang, Qianben

PY - 2015/9/16

Y1 - 2015/9/16

N2 - Glucocorticoids (GCs) have been widely used as coadjuvants in the treatment of solid tumours, but GC treatment may be associated with poor pharmacotherapeutic response or prognosis. The genomic action of GC in these tumours is largely unknown. Here we find that dexamethasone (Dex, a synthetic GC)-regulated genes in triple-negative breast cancer (TNBC) cells are associated with drug resistance. Importantly, these GC-regulated genes are aberrantly expressed in TNBC patients and are associated with unfavourable clinical outcomes. Interestingly, in TNBC cells, Compound A (CpdA, a selective GR modulator) only regulates a small number of genes not involved in carcinogenesis and therapy resistance. Mechanistic studies using a ChIP-exo approach reveal that Dex- but not CpdA-liganded glucocorticoid receptor (GR) binds to a single glucocorticoid response element (GRE), which drives the expression of pro-tumorigenic genes. Our data suggest that development of safe coadjuvant therapy should consider the distinct genomic function between Dex- and CpdA-liganded GR.

AB - Glucocorticoids (GCs) have been widely used as coadjuvants in the treatment of solid tumours, but GC treatment may be associated with poor pharmacotherapeutic response or prognosis. The genomic action of GC in these tumours is largely unknown. Here we find that dexamethasone (Dex, a synthetic GC)-regulated genes in triple-negative breast cancer (TNBC) cells are associated with drug resistance. Importantly, these GC-regulated genes are aberrantly expressed in TNBC patients and are associated with unfavourable clinical outcomes. Interestingly, in TNBC cells, Compound A (CpdA, a selective GR modulator) only regulates a small number of genes not involved in carcinogenesis and therapy resistance. Mechanistic studies using a ChIP-exo approach reveal that Dex- but not CpdA-liganded glucocorticoid receptor (GR) binds to a single glucocorticoid response element (GRE), which drives the expression of pro-tumorigenic genes. Our data suggest that development of safe coadjuvant therapy should consider the distinct genomic function between Dex- and CpdA-liganded GR.

UR - http://www.scopus.com/inward/record.url?scp=84941900818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941900818&partnerID=8YFLogxK

U2 - 10.1038/ncomms9323

DO - 10.1038/ncomms9323

M3 - Article

C2 - 26374485

AN - SCOPUS:84941900818

VL - 6

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 8323

ER -